Chest:糖皮质激素预防成人拔管后喘鸣和再插管 这个可以有

2017-07-25 吴刚 环球医学

2017年5月,发表在《Chest》的一项由日本和中国科学家进行的系统评价和荟萃分析,考察了哪些患者可以从选择性拔管前预防性使用糖皮质激素中获益。



2017年5月,发表在《Chest》的一项由日本和中国科学家进行的系统评价和荟萃分析,考察了哪些患者可以从选择性拔管前预防性使用糖皮质激素中获益。

背景:选择性拔管前使用糖皮质激素可以预防拔管后喘鸣和再插管。研究者更新系统评价,以确定哪些患者可以从选择性拔管前预防性使用糖皮质激素中获益。

方法:研究者检索了PubMed、EMBASE、万方数据库、中国学术期刊网络出版总库和Cochrane临床试验中心注册中从建库至2016年2月29日符合纳入标准的试验。符合纳入标准的随机对照试验为考察机械通气成人患者选择性拔管前全身使用糖皮质激素的有效性和安全性的试验。研究者使用DerSimonian和Laird随机效应模型合并数据。

结果:研究者确定了纳入2472例受试者的11项研究用于分析。与安慰剂或无治疗相比,预防性使用糖皮质激素与拔管后气道事件(风险比[RR],0.43;95% CI,0.29~0.66)和再插管(RR,0.42;95% CI,0.25~0.71)发生率降低相关。该相关性在拔管后进展为气道并发症风险高的受试者中显着,使用气囊漏气测试法确定,拔管后气道事件(RR,0.34;95% CI,0.24~0.48)和再插管(RR,0.35;95% CI,0.20~0.64)发生率降低。非选择性受试者中未发现此相关性。不良事件罕见。

结论:选择性拔管前预防使用糖皮质激素与拔管后气道事件和再插管的发生率显着降低相关,少有不良事件。选择可以从预防性使用糖皮质激素获益的气道阻塞高风险患者是合理的。

原始出处:

Kuriyama A, Umakoshi N, Sun R, et al. Prophylactic Corticosteroids for Prevention of Postextubation Stridor and Reintubation in Adults: A Systematic Review and Meta-analysis. Chest. 2017 May;151(5):1002-1010. doi: 10.1016/j.chest.2017.02.017. Epub 2017 Feb 21.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2050794, encodeId=3a432050e9443, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Dec 21 05:27:00 CST 2017, time=2017-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701168, encodeId=02031e0116814, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sat Jul 07 02:27:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929394, encodeId=aa7a192939484, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri May 04 13:27:00 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468877, encodeId=de3614688e713, content=<a href='/topic/show?id=f1565621ecd' target=_blank style='color:#2F92EE;'>#拔管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56217, encryptionId=f1565621ecd, topicName=拔管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=529b6946794, createdName=steven_u4, createdTime=Thu Jul 27 07:27:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600276, encodeId=af7416002e611, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Thu Jul 27 07:27:00 CST 2017, time=2017-07-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2050794, encodeId=3a432050e9443, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Dec 21 05:27:00 CST 2017, time=2017-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701168, encodeId=02031e0116814, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sat Jul 07 02:27:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929394, encodeId=aa7a192939484, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri May 04 13:27:00 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468877, encodeId=de3614688e713, content=<a href='/topic/show?id=f1565621ecd' target=_blank style='color:#2F92EE;'>#拔管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56217, encryptionId=f1565621ecd, topicName=拔管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=529b6946794, createdName=steven_u4, createdTime=Thu Jul 27 07:27:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600276, encodeId=af7416002e611, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Thu Jul 27 07:27:00 CST 2017, time=2017-07-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2050794, encodeId=3a432050e9443, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Dec 21 05:27:00 CST 2017, time=2017-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701168, encodeId=02031e0116814, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sat Jul 07 02:27:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929394, encodeId=aa7a192939484, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri May 04 13:27:00 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468877, encodeId=de3614688e713, content=<a href='/topic/show?id=f1565621ecd' target=_blank style='color:#2F92EE;'>#拔管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56217, encryptionId=f1565621ecd, topicName=拔管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=529b6946794, createdName=steven_u4, createdTime=Thu Jul 27 07:27:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600276, encodeId=af7416002e611, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Thu Jul 27 07:27:00 CST 2017, time=2017-07-27, status=1, ipAttribution=)]
    2018-05-04 Smile2680
  4. [GetPortalCommentsPageByObjectIdResponse(id=2050794, encodeId=3a432050e9443, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Dec 21 05:27:00 CST 2017, time=2017-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701168, encodeId=02031e0116814, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sat Jul 07 02:27:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929394, encodeId=aa7a192939484, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri May 04 13:27:00 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468877, encodeId=de3614688e713, content=<a href='/topic/show?id=f1565621ecd' target=_blank style='color:#2F92EE;'>#拔管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56217, encryptionId=f1565621ecd, topicName=拔管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=529b6946794, createdName=steven_u4, createdTime=Thu Jul 27 07:27:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600276, encodeId=af7416002e611, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Thu Jul 27 07:27:00 CST 2017, time=2017-07-27, status=1, ipAttribution=)]
    2017-07-27 steven_u4
  5. [GetPortalCommentsPageByObjectIdResponse(id=2050794, encodeId=3a432050e9443, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Dec 21 05:27:00 CST 2017, time=2017-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701168, encodeId=02031e0116814, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sat Jul 07 02:27:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929394, encodeId=aa7a192939484, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri May 04 13:27:00 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468877, encodeId=de3614688e713, content=<a href='/topic/show?id=f1565621ecd' target=_blank style='color:#2F92EE;'>#拔管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56217, encryptionId=f1565621ecd, topicName=拔管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=529b6946794, createdName=steven_u4, createdTime=Thu Jul 27 07:27:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600276, encodeId=af7416002e611, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Thu Jul 27 07:27:00 CST 2017, time=2017-07-27, status=1, ipAttribution=)]

相关资讯

Chest:长期吸入糖皮质激素治疗慢性阻塞性肺疾病与骨折风险的研究

长期服用吸入性糖皮质激素(ICS)治疗慢性阻塞性肺病(COPD)是否会增加骨折风险尚不确定,尤其是女性 - 基于绝经后的骨折风险。研究者评估了慢性阻塞性肺病患者长期使用ICS是否增加髋骨或上肢骨折的风险,同时评估了风险是否存在与性别相关的差异。

JCEM:先天性肾上腺增生症雄激素的排泄的调节——改良的糖皮质激素vs.常规糖皮质激素

替代路径介导的雄激素合成在先天性肾上腺增生症(CAH)中显着增加了雄激素的过剩。改良的氢化可的松通过替代途径弱化主要底物——17OHP来控制雄激素的合成,它比传统的糖皮质激素(GC)治疗要优越。

Fertil Steril:胚泡移植前糖皮质激素和抗菌药物使用对妊娠率有何影响?

2017年6月,发表在《Fertil Steril》的一项由美国科学家进行的回顾性队列研究,考察了胚泡移植(ET)前糖皮质激素和抗菌药物使用的结局。

Ann Rheum Dis:类风湿关节炎管理:如何用药?

2017年6月,发表在《Ann Rheum Dis.》的一项类风湿关节炎(RA)管理的EULAR建议的2016年更新的系统文献回顾调查了糖皮质激素、传统和靶向合成的改善病情抗风湿药的有效性。

Lancet:阿奇霉素对持续哮喘患者哮喘发作及生活质量的影响

持续症状哮喘成人患者口服阿奇霉素治疗48周后哮喘发作减轻,生活质量改善。阿奇霉素有望用于持续性哮喘的治疗

Chest:糖皮质激素预防成人拔管后喘鸣和再插管

2017年5月,发表在《Chest》的一项由日本和中国科学家进行的系统评价和荟萃分析,考察了哪些患者可以从选择性拔管前预防性使用糖皮质激素中获益。